Circio Collaborates with Solid Biosciences to Develop Genetic Heart Disease Gene Therapy
Circio Holding ASA has entered into a collaboration with Solid Biosciences to advance the development of a gene therapy candidate for genetic heart disease.
Stocks · News reference
J.P. Morgan analyst Anupam Rama has maintained a "Buy" rating on Solid Biosciences (SLDB) and set a price target of $11.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Circio Holding ASA has entered into a collaboration with Solid Biosciences to advance the development of a gene therapy candidate for genetic heart disease.
William Blair analyst Alethia Young initiated coverage on Solid Biosciences (SLDB) with a Buy rating and a price target of $11.
Solid Biosciences announced that its President and CEO, Bo Cumbo, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
Solid Biosciences announced that members of its management team will participate in one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026.